Cutaneous Neurofibromatosis Type 1 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Neurofibromatosis 1 (NF1) is a genetic disorder characterized by the development of multiple noncancerous tumors of nerves and skin and areas of abnormal skin color. Areas of abnormal skin pigmentation typically include pale tan or light brown discolorations and freckling in atypical locations such as under the arms or in the groin. Penetrance approaches 100% by age 20; if the patient has the mutation, they will exhibit manifestations, although expressivity is highly variable, even among family members with the same mutation.

·       It affects males and females both in equal numbers. NF1 affects all races and ethnic groups equally and is estimated to occur in 1 in 2,500 to 3,000 births.

·       The disorder is inherited from a parent in about 50% of individuals with NF1. Only one parent need to be affected to cause a child to have NF1.

Thelansis’s “Cutaneous Neurofibromatosis Type 1 Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cutaneous Neurofibromatosis Type 1 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Cutaneous Neurofibromatosis Type 1 across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Cutaneous Neurofibromatosis Type 1 Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Cutaneous Neurofibromatosis Type 1 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033